Franco Granella
Università degli Studi di Parma
H-index: 53
Europe-Italy
Top articles of Franco Granella
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry | Journal of Neurology | Pietro Iaffaldano Giuseppe Lucisano Tommaso Guerra Francesco Patti Eleonora Cocco | 2024/3 |
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) | Journal of Neurology | Alessia Bianchi Domenica Matranga Francesco Patti Laura Maniscalco Silvy Pilotto | 2024/2/16 |
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom | Journal of medical economics | T Spelman WL Herring C Acosta R Hyde VG Jokubaitis | 2024/12/31 |
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience | Current Neuropharmacology | Aurora Zanghì Diana Ferraro Graziella Callari Paola Valentino Franco Granella | 2024/2/1 |
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries | The Lancet Child & Adolescent Health | Sifat Sharmin Izanne Roos Charles B Malpas Pietro Iaffaldano Marta Simone | 2024/5/1 |
Multiple Sclerosis Progression and Relapse Activity in Children | JAMA neurology | Pietro Iaffaldano Emilio Portaccio Giuseppe Lucisano Marta Simone Alessia Manni | 2024/1/1 |
Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010) | Journal of Neurology | Alvino Bisecco Federica Matrone Marco Capobianco Giovanna De Luca Massimo Filippi | 2024/2 |
Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study | Journal of Neurology | Massimo Filippi Luigi Grimaldi Antonella Conte Rocco Totaro Maria Rosaria Valente | 2024/1 |
Comparative effectiveness in multiple sclerosis: A methodological comparison | Multiple Sclerosis Journal | Izanne Roos Ibrahima Diouf Sifat Sharmin Dana Horakova Eva Kubala Havrdova | 2023/3 |
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial | Journal of Neurology, Neurosurgery & Psychiatry | Ibrahima Diouf Charles B Malpas Sifat Sharmin Izanne Roos Dana Horakova | 2023/12/1 |
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity | Multiple Sclerosis and Related Disorders | Tim Spelman Dana Horakova Serkan Ozakbas Raed Alroughani Marco Onofrj | 2023/2/1 |
Prevalence of 2-year “No evidence of disease activity”(NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study | Multiple Sclerosis and Related Disorders | V Bazzurri A Fiore E Curti E Tsantes A Franceschini | 2023/11/1 |
Disability accrual in primary and secondary progressive multiple sclerosis | Journal of Neurology, Neurosurgery & Psychiatry | Sam Harding-Forrester Izanne Roos Ai-Lan Nguyen Charles B Malpas Ibrahima Diouf | 2023/9/1 |
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis | European Journal of Neurology | Ibrahima Diouf Charles B Malpas Sifat Sharmin Izanne Roos Dana Horakova | 2023/4 |
Hematopoietic stem cell transplantation in people with active secondary progressive multiple sclerosis | Neurology | Giacomo Boffa Alessio Signori Luca Massacesi Alice Mariottini Elvira Sbragia | 2023/3/14 |
Ocrelizumab in tumefactive multiple sclerosis onset. A case report | Neuroimmunology Reports | V Bazzurri E Curti E Tsantes A Fiore A Franceschini | 2022/1/1 |
Risk of getting COVID-19 in people with multiple sclerosis: a case-control study | Neurology: Neuroimmunology & Neuroinflammation | Pietro Iaffaldano Giuseppe Lucisano Alessia Manni Damiano Paolicelli Francesco Patti | 2022/1/19 |
Comparing the natural history of pediatric multiple sclerosis with onset before or after pubertal age (P1-5.005) | Ermelinda De Meo Massimo Filippi Maria Trojano Giancarlo Comi Francesco Patti | 2022/5/3 | |
Confirmed disability progression as a marker of permanent disability in multiple sclerosis | European journal of neurology | Sifat Sharmin Francesca Bovis Charles Malpas Dana Horakova Eva Kubala Havrdova | 2022/8 |
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: a study from the Italian MS register | Multiple Sclerosis Journal | Pietro Iaffaldano Giuseppe Lucisano Tommaso Guerra Francesco Patti Marco Onofrj | 2022/12 |
